US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ensysce Biosciences Inc.

1.76

-0.1200-6.38%

Post-market: 1.790.0300+1.70%19:55 EDT

Volume:133.33K

Turnover:233.60K

Market Cap:2.89M

PE:-0.15

High:1.82

Open:1.80

Low:1.71

Close:1.88

Loading ...

Overview Company News Filings

Ensysce Biosciences files to sell 652,439 shares of common Stock for holders

Ensysce Biosciences announces data from opioid overdose protection study

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

ACCESS Newswire

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ACCESS Newswire

Ensysce Biosciences announces PAINWeek 2025 Symposium

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

ACCESS Newswire

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

ENSC Starts 2025 in Great Shape

Zacks Small Cap Research

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

ACCESS Newswire

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

ACCESS Newswire

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

ACCESS Newswire

When Can We Expect A Profit From Ensysce Biosciences, Inc. (NASDAQ:ENSC)?

Simply Wall St.

Ensysce Biosciences announces interim data for PF614-MPAR

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

ACCESS Newswire

ENSC Continues to Announce Potential Life-Changing Results

Zacks Small Cap Research

Ensysce focused on clinical development milestones for PF614, PF614-MPAR

Ensysce Biosciences Issues Annual Shareholder Letter

Ensysce Biosciences Regains Full Compliance With Nasdaq Listing Rules

MT Newswires Live

Ensysce Biosciences Regains Full Compliance with Nasdaq

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ENSC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ENSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENSC\",,,,,undefined,":{"symbol":"ENSC","market":"US","secType":"STK","nameCN":"Ensysce Biosciences Inc.","latestPrice":1.76,"timestamp":1744920000000,"preClose":1.88,"halted":0,"volume":133329,"hourTrading":{"tag":"盘后","latestPrice":1.79,"preClose":1.76,"latestTime":"19:55 EDT","volume":3453,"amount":6077.336,"timestamp":1744934121764},"delay":0,"floatShares":1136100,"shares":1644728,"eps":-11.448165,"marketStatus":"Market Closed","change":-0.12,"latestTime":"04-17 16:00:00 EDT","open":1.8,"high":1.82,"low":1.71,"amount":233598.807792,"amplitude":0.058511,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-11.448165,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.88,"preHourTrading":{"tag":"盘前","latestPrice":1.8,"preClose":1.88,"latestTime":"09:29 EDT","volume":4866,"amount":8576.4899574,"timestamp":1744896598422},"postHourTrading":{"tag":"盘后","latestPrice":1.79,"preClose":1.76,"latestTime":"19:55 EDT","volume":3453,"amount":6077.336,"timestamp":1744934121764},"volumeRatio":0.2521095638176457,"impliedVol":3.1521,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENSC\",,,,,undefined,":{"symbol":"ENSC","floatShares":1136100,"roa":"-101.29%","roe":"-585.41%","lyrEps":-11.448165,"volumeRatio":0.2521095638176457,"shares":1644728,"dividePrice":0,"high":1.82,"amplitude":0.058511,"preClose":1.88,"low":1.71,"week52Low":1.7,"pbRate":"0.78","psRate":"0.56","week52High":14.67,"institutionHeld":0,"latestPrice":1.76,"eps":-11.448165,"divideRate":0,"volume":133329,"delay":0,"ttmEps":-11.448165,"open":1.8,"prevYearClose":8.14,"prevWeekClose":2.03,"prevMonthClose":2.56,"prevQuarterClose":2.56,"fiveDayClose":1.88,"twentyDayClose":3.56,"sixtyDayClose":8.28},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENSC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528085292","title":"Ensysce Biosciences files to sell 652,439 shares of common Stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2528085292","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528085292?lang=en_us&edition=fundamental","pubTime":"2025-04-17 04:35","pubTimestamp":1744835745,"startTime":"0","endTime":"0","summary":"16:33 EDT Ensysce Biosciences (ENSC) files to sell 652,439 shares of common Stock for holders Published first on TheFly – the ultimate source for r...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-files-to-sell-652439-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-files-to-sell-652439-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2527941540","title":"Ensysce Biosciences announces data from opioid overdose protection study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527941540","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527941540?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:36","pubTimestamp":1744720579,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences (ENSC) announced completion of Part 1 of its second clinical trial to evaluate PF614-MPAR for overdose protection. PF614-MPAR-1...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-announces-data-from-opioid-overdose-protection-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-announces-data-from-opioid-overdose-protection-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2527134184","title":"Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527134184","media":"ACCESS Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527134184?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"~ Additional Evidence of PF614-MPAR Overdose Protection after Completion of Part 1 of Clinical Study ~SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Ensysce Biosciences, Inc.  , a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced completion of Part 1 of its second clinical trial to evaluate PF614-MPAR for overdose protection. PF614-MPAR-102 demonstrated that the combined Ensysce TAAPTM and MPAR technologies can deliver strong relief for severe pain yet protect from the risk of excessive doses when consumed accidentally or deliberately.The trial will now continue to enroll Part 2 to examine potential food effect and Part 3 to evaluate repeat dosing of PF614 vs. PF614-MPAR. The aggregate data will allow the Company to focus on perfecting a final drug product to move into commercialization.Dr. Lynn Kirkpatrick, CEO of Ensysce, added, \"Each phase of our MPAR related cl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-announces-positive-data-120000101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2523949968","title":"Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2523949968","media":"ACCESS Newswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523949968?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.The gross proceeds to the Company from the offering are expected to be approximately $1.1 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering for continued development of its TAAPTM and MPAR programs and for working capital.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-inc-announces-1-120000466.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USJW.SI","BK4585","IE00B3QW5Z07.USD","QID","PSQ","NVIW.SI","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP","ENSC","QLD","LU2210149790.SGD","NQmain","IE00BGHQF748.EUR","IE00BKPKM429.USD",".IXIC","TSYW.SI","BK4588","MNQmain","TQQQ","USAW.SI","BK4139","BK4112","LU2095319765.USD","SQQQ"],"gpt_icon":1},{"id":"2520769926","title":"Ensysce Biosciences announces PAINWeek 2025 Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2520769926","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520769926?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:37","pubTimestamp":1742301441,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences (ENSC) will host a symposium on Wednesday, September 3, 2025, during PAINWeek 2025, designed to share perspectives with experts...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-announces-painweek-2025-symposium?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-announces-painweek-2025-symposium?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2520678289","title":"Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2520678289","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520678289?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:00","pubTimestamp":1742299200,"startTime":"0","endTime":"0","summary":"~ Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics ~~ Panel Discussion Posted to Ensysce's Corporate Website ~SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 / Ensysce Biosciences, Inc.  , a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, announced it will host a symposium on Wednesday, September 3, 2025, during PAINWeek 2025, designed to share perspectives with experts in the field of pain management. In preparation for this meeting, the company recently hosted a panel discussion entitled \"The State of the Nation in Pain: A Discussion on Analgesics and Their Optimal Uses\".About Ensysce BiosciencesEnsysce Biosciences is a clinical-stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection  and Multi-Pill Abuse Resist","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-announces-painweek-2025-120000264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BGHQF748.EUR","STT","BK4139","ENSC","IE00B64PRP62.GBP","BK4588","LU0061475181.USD","LU1883839398.USD","LU1894683264.USD","BK4585","IE0034235188.USD","LU1894683348.USD","IE00B3QW5Z07.USD","BK4135"],"gpt_icon":0},{"id":"2519839379","title":"Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2519839379","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519839379?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:00","pubTimestamp":1741867200,"startTime":"0","endTime":"0","summary":"New York, NY, March 13, 2025  -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. . The update note includes information on Ensysce Biosciences’ business model, services, industry, financial results, valuation, and risks.PF614-MPAR Clinical Program Update : The company also reported notable interim results from the ongoing PF614-MPAR-102 clinical trial. PF614-MPAR combines the TAAP prodrug PF614 with a trypsin inhibitor through its Multi-Pill Abuse Resistance  technology. Interim data revealed that the 100 mg dosage form of PF614-MPAR provided effective overdose protection when excessive doses were consumed. Supported by the National Institute on Drug Abuse, the study continues with higher dosage levels and additional safety evaluations. This innovative combination recently earned the FDA’s Breakthrough Therapy designation in January 2024, reflecting its potential to si","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/diamond-equity-research-releases-note-120000115.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USJW.SI","IE00B64PRP62.GBP","SQQQ","BK4585","BK4112","TQQQ","IE00BGHQF748.EUR","IE00BKPKM429.USD","EQR","LU2095319765.USD","TSYW.SI","MNQmain","NVIW.SI","BK4588","NQmain","BK4215","QID","LU2210150020.SGD","NDAQ","QLD","USAW.SI",".IXIC","LU2210149790.SGD","IE00B3QW5Z07.USD","PSQ","ENSC","BK4139"],"gpt_icon":1},{"id":"2518827722","title":"ENSC Starts 2025 in Great Shape","url":"https://stock-news.laohu8.com/highlight/detail?id=2518827722","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518827722?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:08","pubTimestamp":1741691280,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences  released its 4Q2024 results that showed a good cash balance of $3.5 million due in large part to the financing activities management has undertaken which we’ve described in earlier reports, as well as a focus on controlling administrative expenses.Management also noted that it has received positive feedback on its Phase 3 study design for PF614 and is planning on starting enrollment in this crucial study in 2Q2025. Management also noted that the company remains on track for a New Drug Application submission in 2026. Additionally, earlier this year, the company announced a critical partnership for the manufacturing and commercialization of both of the companies’ products.Ensysce Biosciences continues to be one of the companies that we cover that we believe most of America would hope is successful and one we are becoming more conv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensc-starts-2025-great-shape-110800728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2518786959","title":"Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2518786959","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518786959?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:15","pubTimestamp":1741637700,"startTime":"0","endTime":"0","summary":"Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR. Groundbreaking Trial on PF614-MPAR Generates Positive Interim Results. Our lead product, PF614, is a Trypsin-Activated Abuse Protection  extended-release oxycodone and a potential \"next generation\" analgesic to treat severe pain. PF614's TAAPTM chemical modification of oxycodone makes it inactive until it is swallowed and exposed to the body's own trypsin in the small intestine to activate or \"switch on\" to release oxycodone. The Company's TAAPTM technology is designed to control release, be highly resistant to tampering, and reduce abuse, with a goal of providing what the company believes is a safer effective opioid product for those suffering with severe pa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-reports-fourth-quarter-201500430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2517078911","title":"Ensysce Biosciences to Participate in the 37th Annual ROTH Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2517078911","media":"ACCESS Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517078911?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:00","pubTimestamp":1741179600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ensysce Biosciences, Inc.  , a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced its participation in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA.Ensysce's Chief Executive Officer Dr. Lynn Kirkpatrick, Chief Financial Officer Dave Humphrey, and Chief Commercial Officer Geoff Birkett will be available to host one-on-one meetings with investors during the event. In addition, management will participate in a fireside chat on Tuesday, March 18th at 11:30am PT. Interested parties can access the fireside chat here.To schedule a one-on-one meeting with Ensysce's management, please contact Investor Relations at ENSC@mzgroup.us or your ROTH representative.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-participate-37th-annual-130000932.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ENSC","ROTH"],"gpt_icon":0},{"id":"2516632770","title":"Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids","url":"https://stock-news.laohu8.com/highlight/detail?id=2516632770","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516632770?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:43","pubTimestamp":1741012980,"startTime":"0","endTime":"0","summary":"NEW YORK, March 3, 2025 /PRNewswire/ --Today's Marketplace  is proud to announce a featured interview with Ensysce Biosciences  CEO Dr. Lynn Kirkpatrick and Dr. Neel Pathak, DS, Program Director with Creighton University. The doctors joined TMP's host Jane King to discuss the ongoing issues with opioids for pain management and how \"clever chemistry\" is being used to introduce safer opioids that are less prone to accidental overdose and abuse.The full interview can be viewed online here.\"Our team uses what I like to call 'clever chemistry' to create the next generation of opioids,\" she told King. \"The clever chemistry is designed to not only reduce abuse but to make these products safer, so patients in pain can have less fear and higher confidence level in taking opioid medications when they need them.\". That \"clever\" chemical engineering also includes built-in safeguards against overdose that prevent the medication from being released if more than the prescribed dosage is ingested. All","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/ensysce-biosciences-ceo-dr-lynn-144300673.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-ceo-dr-lynn-144300673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NYSE","TMP","BK4211","ENSC","BK4139"],"gpt_icon":0},{"id":"2509928590","title":"Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2509928590","media":"ACCESS Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509928590?lang=en_us&edition=fundamental","pubTime":"2025-02-05 21:00","pubTimestamp":1738760400,"startTime":"0","endTime":"0","summary":"~ Positive Enrollment Progress and Safety Data ~~ FDA Attention Establishes Momentum in the Pain Treatment Space ~SAN DIEGO, CA / ACCESS Newswire / February 5, 2025 / Ensysce Biosciences, Inc.  , a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced continued subject enrollment and successful dosing augmenting the progress of its second clinical trial to evaluate PF614-MPAR for overdose protection.About Ensysce BiosciencesEnsysce Biosciences is a clinical stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection  and Multi-Pill Abuse Resistance  platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-reports-continued-positive-130000682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065732104.USD","ENSC","PRGS","BK4097","BK4139"],"gpt_icon":0},{"id":"2508945180","title":"When Can We Expect A Profit From Ensysce Biosciences, Inc. (NASDAQ:ENSC)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2508945180","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508945180?lang=en_us&edition=fundamental","pubTime":"2025-02-04 21:27","pubTimestamp":1738675668,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Ensysce Biosciences, Inc.'s  future prospects. Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. The US$9.0m market-cap company’s loss lessened since it announced a US$11m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$7.9m, as it approaches breakeven. The most pressing concern for investors is Ensysce Biosciences' path to profitability – when will it breakeven?In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.According to the 2 industry analysts covering Ensysce Biosciences, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$28m in 2026. The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/expect-profit-ensysce-biosciences-inc-132748820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4139","PSQ","TSYW.SI","LU2210150020.SGD","IE00BGHQF748.EUR","QID","IE00BKPKM429.USD","ENSC","QLD","USAW.SI","NQmain","IE00B64PRP62.GBP","TQQQ","LU2095319765.USD","LU2210149790.SGD","MNQmain","NVIW.SI","IE00B3QW5Z07.USD","USJW.SI","NDAQ","SQQQ","BK4112",".IXIC","BK4588"],"gpt_icon":1},{"id":"2505747488","title":"Ensysce Biosciences announces interim data for PF614-MPAR","url":"https://stock-news.laohu8.com/highlight/detail?id=2505747488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505747488?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:20","pubTimestamp":1737552015,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences (ENSC) announced interim data from its second clinical trial to evaluate PF614-MPAR for overdose protection. Clinical study PF6...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-announces-interim-data-for-pf614-mpar?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-announces-interim-data-for-pf614-mpar?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2505974788","title":"Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR","url":"https://stock-news.laohu8.com/highlight/detail?id=2505974788","media":"ACCESS Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505974788?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550800,"startTime":"0","endTime":"0","summary":"~ Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Ensysce Biosciences, Inc.  , a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced interim data from its second clinical trial to evaluate PF614-MPAR for overdose protection. Clinical study PF614-MPAR-102, ‘A Single and Multiple Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 when PF614 Capsule is CoAdministered with Nafamostat as a Combination of Immediate Release Solution and Extended Release Capsule Formulations  in Healthy Subjects,' was designed to evaluate the full dosage range of PF614-MPAR, study potential food effects, and to conduct a multiple ascending dose study with the final PF614-MPAR combination. In 2024, PF614-MPAR received Breakthrough Therapy designation from the U.S. Food and Drug Administ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-announces-positive-interim-130000627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2505720254","title":"ENSC Continues to Announce Potential Life-Changing Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2505720254","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505720254?lang=en_us&edition=fundamental","pubTime":"2025-01-22 19:06","pubTimestamp":1737543960,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences  is a clinical stage company that is developing treatments designed to have the same pain-relieving capabilities as opioids but come with the ability to inhibit abuse and overdoses. Opioid abuse is a national crisis, with the CDC estimating over 75,000 deaths from opioid overdoses and there are also exponentially more lives negatively impacted by opioid abuse.Testing on these treatments continues and the company recently announced encouraging interim results from its second clinical trial evaluating PF614-MPAR for overdose protection. The headline from the release is that “The subjects receiving the MPAR product had a significantly lower total maximum blood concentration of oxycodone compared to PF614 alone, an indication of overdose protection. This news continues a string of positive test results that continue to illustrate the potential of ENSC pain treatments to be game changers. The company also commented that there were no adverse events reported during testin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensc-continues-announce-potential-life-110600665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2501093727","title":"Ensysce focused on clinical development milestones for PF614, PF614-MPAR","url":"https://stock-news.laohu8.com/highlight/detail?id=2501093727","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501093727?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:51","pubTimestamp":1736344283,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences (ENSC) issued a letter to shareholders from CEO Lynn Kirkpatrick, which read, in part, “2024 was underscored by outstanding pro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ensysce-focused-on-clinical-development-milestones-for-pf614-pf614-mpar?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ensysce-focused-on-clinical-development-milestones-for-pf614-pf614-mpar?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2501772013","title":"Ensysce Biosciences Issues Annual Shareholder Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2501772013","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501772013?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:00","pubTimestamp":1736341200,"startTime":"0","endTime":"0","summary":"~ FDA Breakthrough Therapy designation received for PF614-MPAR ~~ PF614-MPAR second clinical trial initiated ~~ Lead clinical candidate identified for OUD program ~~ PF614 Phase 3 trial poised to commence 1H 2025 ~SAN DIEGO, CA / ACCESSWIRE / January 8, 2025 / Ensysce Biosciences, Inc.  , a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick.In 2024, we made significant progress toward our development milestones for PF614. Early in 2024, we completed a regulatory End of Phase 2 meeting with the FDA, an important discussion about our program which provided feedback","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-issues-annual-shareholder-130000054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZL793.SGD","IE00B19Z4B17.USD","BK4139","ENSC","CTS","IE0031619046.USD","IE00B66KJ199.SGD","BK4145"],"gpt_icon":0},{"id":"2493760368","title":"Ensysce Biosciences Regains Full Compliance With Nasdaq Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2493760368","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493760368?lang=en_us&edition=fundamental","pubTime":"2024-12-24 00:30","pubTimestamp":1734971426,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences  said Monday it has regained compliance with Nasdaq's minimum stock price requirement for continued listing.The pharmaceutical company said that since it had earlier regained compliance the exchange's stockholders' equity rule, it has now met all requirements outlined in a recent hearings panel decision, so its stock will continue trading on the Nasdaq Capital Market.Price: 8.29, Change: +0.19, Percent Change: +2.35","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2095319765.USD","NDAQ","BK4139","BK4112","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","ENSC","LU2210149790.SGD","BK4585","NQmain","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD",".IXIC"],"gpt_icon":0},{"id":"2493264769","title":"Ensysce Biosciences Regains Full Compliance with Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2493264769","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493264769?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:00","pubTimestamp":1734958800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc.  , a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that on December 20, 2024, it received notice from The Nasdaq Stock Market LLC  that the Company has demonstrated compliance with the minimum bid price requirement in Listing Rule 5550. Ensysce had previously regained compliance with the stockholders' equity requirement in Listing Rule 5550. As a result, the Company has met all requirements outlined in the Nasdaq Hearings Panel decision dated November 5, 2024, and Ensysce common stock will continue trading on The Nasdaq Capital Market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-regains-full-compliance-130000804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","ENSC","USJW.SI","USAW.SI","BK4112","IE00B64PRP62.GBP","NQmain","LU2095319765.USD",".IXIC","TQQQ","IE00BKPKM429.USD","QLD","IE00B3QW5Z07.USD","LU2210149790.SGD","NVIW.SI","BK4585","IE00BGHQF748.EUR","SQQQ","LU2210150020.SGD","QID","BK4139","MNQmain","BK4588","NDAQ","PSQ"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENSC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-10","symbol":"ENSC","fiscalQuarterEnding":"2024/12","expectedEps":-2.74,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741579200000,"reportTimeType":"post","actualEps":-2.9},{"market":"US","date":"2024-12-06","symbol":"ENSC","defaultRemindTime":1733495400000,"type":"split","dateTimestamp":1733461200000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-12","symbol":"ENSC","fiscalQuarterEnding":"2024/09","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-08-14","symbol":"ENSC","fiscalQuarterEnding":"2024/06","expectedEps":-0.39,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.22},{"date":"2024-05-13","symbol":"ENSC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715587200000,"name":null,"time":"Pre-Market","dateTimestamp":1715572800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ENSC\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ENSC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ENSC","date":"2025-04-17","current":-0.330747,"percent":0.557359,"low":-1151.871294,"twenty":-1.241359,"median":-0.377888,"eighty":-0.214536,"high":2051.953734,"avg":-10.613159,"sd":301.554937,"marketCap":2641651},"quantilePoints":[{"date":"2021-07-02","current":2051.953734,"twenty":2050.538593,"median":2050.538593,"eighty":2051.387678,"marketCap":353522901},{"date":"2021-07-09","current":1665.538105,"twenty":1670.376702,"median":2037.802329,"eighty":2050.538593,"marketCap":286948898},{"date":"2021-07-16","current":1373.799461,"twenty":1582.794518,"median":1666.827366,"eighty":2047.99134,"marketCap":236686414},{"date":"2021-07-23","current":986.303472,"twenty":1176.265418,"median":1592.804232,"eighty":1966.125264,"marketCap":169926280},{"date":"2021-07-30","current":796.099172,"twenty":905.447974,"median":1416.070215,"eighty":1677.156928,"marketCap":137156742},{"date":"2021-08-06","current":598.835663,"twenty":785.954194,"median":1130.038123,"eighty":1667.600922,"marketCap":103171001},{"date":"2021-08-13","current":462.160228,"twenty":607.289814,"median":986.310516,"eighty":1664.774414,"marketCap":79623737},{"date":"2021-08-20","current":-800.661067,"twenty":514.012352,"median":880.640679,"eighty":1647.936568,"marketCap":79073287},{"date":"2021-08-27","current":-761.364824,"twenty":-747.61113,"median":789.758561,"eighty":1590.301804,"marketCap":75192390},{"date":"2021-09-03","current":-825.221223,"twenty":-767.750462,"median":676.332041,"eighty":1555.901866,"marketCap":81498848},{"date":"2021-09-10","current":-859.605437,"twenty":-780.52174,"median":598.835663,"eighty":1458.340968,"marketCap":84894633},{"date":"2021-09-17","current":-724.524585,"twenty":-780.52174,"median":555.860395,"eighty":1373.799461,"marketCap":71554048},{"date":"2021-09-24","current":-1102.750982,"twenty":-800.661067,"median":488.931707,"eighty":1361.174599,"marketCap":108907687},{"date":"2021-10-01","current":-704.876458,"twenty":-815.397165,"median":-708.560485,"eighty":1130.038123,"marketCap":69613599},{"date":"2021-10-08","current":-582.075678,"twenty":-800.661067,"median":-611.547874,"eighty":1000.40781,"marketCap":57485794},{"date":"2021-10-15","current":-582.075678,"twenty":-788.380994,"median":-604.17982,"eighty":986.317559,"marketCap":57485794},{"date":"2021-10-22","current":-547.691464,"twenty":-781.01294,"median":-601.723805,"eighty":986.303472,"marketCap":54090009},{"date":"2021-10-29","current":-540.32342,"twenty":-780.52174,"median":-596.811776,"eighty":885.234099,"marketCap":53362341},{"date":"2021-11-05","current":-552.603493,"twenty":-778.556926,"median":-582.075678,"eighty":880.640679,"marketCap":54575121},{"date":"2021-11-12","current":-542.779435,"twenty":-776.100911,"median":-575.935642,"eighty":879.231656,"marketCap":53604897},{"date":"2021-11-19","current":-2.041392,"twenty":-776.100911,"median":-559.971547,"eighty":796.099172,"marketCap":38445141},{"date":"2021-11-26","current":-2.034952,"twenty":-774.1361,"median":-555.059508,"eighty":785.954194,"marketCap":38323863},{"date":"2021-12-03","current":-1.609931,"twenty":-769.715274,"median":-550.147479,"eighty":769.891308,"marketCap":30319512},{"date":"2021-12-10","current":-5.705594,"twenty":-764.803244,"median":-542.779435,"eighty":694.367562,"marketCap":107452350},{"date":"2021-12-17","current":-3.812316,"twenty":-763.820838,"median":-539.095413,"eighty":648.151541,"marketCap":71796604},{"date":"2021-12-23","current":-6.594276,"twenty":-762.34723,"median":-537.867406,"eighty":615.743964,"marketCap":124188721},{"date":"2021-12-31","current":-6.053339,"twenty":-758.417601,"median":-6.594276,"eighty":588.690681,"marketCap":114001365},{"date":"2022-01-07","current":-5.138899,"twenty":-754.979176,"median":-6.175695,"eighty":578.5457,"marketCap":96779882},{"date":"2022-01-14","current":-4.224458,"twenty":-753.99677,"median":-5.705594,"eighty":551.774222,"marketCap":79558399},{"date":"2022-01-21","current":-3.078187,"twenty":-753.99677,"median":-5.692715,"eighty":524.720941,"marketCap":57970907},{"date":"2022-01-28","current":-2.150867,"twenty":-750.067147,"median":-5.409367,"eighty":500.767517,"marketCap":40506868},{"date":"2022-02-04","current":-2.073591,"twenty":-736.313461,"median":-5.254814,"eighty":478.223115,"marketCap":39051531},{"date":"2022-02-11","current":-2.073591,"twenty":-719.612556,"median":-4.939267,"eighty":276.652164,"marketCap":39051531},{"date":"2022-02-18","current":-1.39742,"twenty":-709.29729,"median":-4.623721,"eighty":-1.482424,"marketCap":26317336},{"date":"2022-02-25","current":-1.40386,"twenty":-687.68435,"median":-4.456288,"eighty":-1.367797,"marketCap":26438614},{"date":"2022-03-04","current":-1.378101,"twenty":-617.442308,"median":-4.218019,"eighty":-1.378101,"marketCap":25953502},{"date":"2022-03-11","current":-1.416739,"twenty":-611.056671,"median":-4.17294,"eighty":-1.367797,"marketCap":26681170},{"date":"2022-03-18","current":-1.584172,"twenty":-608.600654,"median":-3.915351,"eighty":-1.367797,"marketCap":29834399},{"date":"2022-03-25","current":-1.455377,"twenty":-606.635834,"median":-3.72216,"eighty":-1.378101,"marketCap":27408838},{"date":"2022-04-01","current":-0.909052,"twenty":-605.653428,"median":-3.026669,"eighty":-1.367797,"marketCap":26438614},{"date":"2022-04-08","current":-0.942412,"twenty":-601.723805,"median":-2.640286,"eighty":-1.243923,"marketCap":27408838},{"date":"2022-04-14","current":-0.892372,"twenty":-601.723805,"median":-2.31186,"eighty":-1.109211,"marketCap":25953502},{"date":"2022-04-22","current":-0.884033,"twenty":-599.267791,"median":-2.221704,"eighty":-0.942412,"marketCap":25710946},{"date":"2022-04-29","current":-0.917392,"twenty":-599.267791,"median":-2.189506,"eighty":-0.917392,"marketCap":26681170},{"date":"2022-05-06","current":-0.935552,"twenty":-594.355761,"median":-2.131548,"eighty":-0.917392,"marketCap":27209326},{"date":"2022-05-13","current":-0.797005,"twenty":-582.075678,"median":-2.08647,"eighty":-0.892372,"marketCap":23214444},{"date":"2022-05-20","current":-0.624837,"twenty":-582.075678,"median":-2.073591,"eighty":-0.867353,"marketCap":18199682},{"date":"2022-05-27","current":-0.62899,"twenty":-582.075678,"median":-2.041392,"eighty":-0.82967,"marketCap":18320644},{"date":"2022-06-03","current":-0.645958,"twenty":-578.146055,"median":-2.034952,"eighty":-0.778733,"marketCap":18814863},{"date":"2022-06-10","current":-0.587461,"twenty":-575.198838,"median":-1.960895,"eighty":-0.698325,"marketCap":17111019},{"date":"2022-06-17","current":-0.537744,"twenty":-566.848388,"median":-1.931917,"eighty":-0.663661,"marketCap":15662924},{"date":"2022-06-24","current":-0.547118,"twenty":-561.936359,"median":-1.803122,"eighty":-0.641971,"marketCap":15935954},{"date":"2022-07-01","current":-0.675147,"twenty":-559.971547,"median":-1.758044,"eighty":-0.628942,"marketCap":19665057},{"date":"2022-07-08","current":-0.740288,"twenty":-558.006731,"median":-1.63569,"eighty":-0.63179,"marketCap":21562441},{"date":"2022-07-15","current":-0.73318,"twenty":-554.077102,"median":-1.584172,"eighty":-0.639978,"marketCap":21355409},{"date":"2022-07-22","current":-0.750097,"twenty":-552.603493,"median":-1.526215,"eighty":-0.650372,"marketCap":21848142},{"date":"2022-07-29","current":-0.645214,"twenty":-550.638681,"median":-1.455377,"eighty":-0.648267,"marketCap":18793198},{"date":"2022-08-05","current":-0.542837,"twenty":-547.691464,"median":-1.436058,"eighty":-0.628919,"marketCap":15811251},{"date":"2022-08-12","current":-0.502219,"twenty":-545.726652,"median":-1.416739,"eighty":-0.623627,"marketCap":18104172},{"date":"2022-08-19","current":-0.4432,"twenty":-541.797029,"median":-1.400842,"eighty":-0.597747,"marketCap":15976634},{"date":"2022-08-26","current":-0.437558,"twenty":-540.32342,"median":-1.39098,"eighty":-0.585573,"marketCap":15773232},{"date":"2022-09-02","current":-0.436493,"twenty":-539.341014,"median":-1.39098,"eighty":-0.574176,"marketCap":15734855},{"date":"2022-09-09","current":-0.364844,"twenty":-537.867406,"median":-1.38776,"eighty":-0.560252,"marketCap":13152036},{"date":"2022-09-16","current":-0.333012,"twenty":-537.867406,"median":-1.378101,"eighty":-0.543432,"marketCap":12004543},{"date":"2022-09-23","current":-0.234109,"twenty":-537.376203,"median":-1.352342,"eighty":-0.508327,"marketCap":8439255},{"date":"2022-09-30","current":-0.228893,"twenty":-429.647968,"median":-1.243734,"eighty":-0.498322,"marketCap":8251204},{"date":"2022-10-07","current":-0.234216,"twenty":-6.555638,"median":-1.18844,"eighty":-0.457146,"marketCap":8443092},{"date":"2022-10-14","current":-0.220376,"twenty":-6.367598,"median":-1.109211,"eighty":-0.440474,"marketCap":7944182},{"date":"2022-10-21","current":-0.210262,"twenty":-6.210469,"median":-1.003086,"eighty":-0.435641,"marketCap":7579594},{"date":"2022-10-28","current":-0.250893,"twenty":-6.104857,"median":-0.950752,"eighty":-0.392333,"marketCap":9044283},{"date":"2022-11-04","current":-0.17653,"twenty":-5.98379,"median":-0.934812,"eighty":-0.354113,"marketCap":6363632},{"date":"2022-11-11","current":-0.1248,"twenty":-5.705594,"median":-0.917392,"eighty":-0.266963,"marketCap":4498831},{"date":"2022-11-18","current":-0.202801,"twenty":-5.703018,"median":-0.904882,"eighty":-0.252442,"marketCap":5824224},{"date":"2022-11-25","current":-0.338332,"twenty":-5.692715,"median":-0.892372,"eighty":-0.252314,"marketCap":9716511},{"date":"2022-12-02","current":-0.220875,"twenty":-5.666956,"median":-0.884033,"eighty":-0.252314,"marketCap":6343293},{"date":"2022-12-09","current":-0.218547,"twenty":-5.525282,"median":-0.867353,"eighty":-0.245714,"marketCap":6276429},{"date":"2022-12-16","current":-0.173271,"twenty":-5.293452,"median":-0.82967,"eighty":-0.238048,"marketCap":4976162},{"date":"2022-12-23","current":-0.160808,"twenty":-5.254814,"median":-0.801912,"eighty":-0.234216,"marketCap":4618230},{"date":"2022-12-30","current":-0.167485,"twenty":-5.254814,"median":-0.794791,"eighty":-0.233587,"marketCap":4809988},{"date":"2023-01-06","current":-0.162144,"twenty":-5.208448,"median":-0.777262,"eighty":-0.229014,"marketCap":4656609},{"date":"2023-01-13","current":-0.172083,"twenty":-5.154354,"median":-0.761172,"eighty":-0.22176,"marketCap":4942034},{"date":"2023-01-20","current":-0.151312,"twenty":-4.979194,"median":-0.754483,"eighty":-0.220248,"marketCap":4345527},{"date":"2023-01-27","current":-0.15636,"twenty":-4.713877,"median":-0.749721,"eighty":-0.212142,"marketCap":4490485},{"date":"2023-02-03","current":-0.285115,"twenty":-4.654632,"median":-0.740288,"eighty":-0.212142,"marketCap":8188175},{"date":"2023-02-10","current":-0.319777,"twenty":-4.577355,"median":-0.716973,"eighty":-0.2146,"marketCap":9183632},{"date":"2023-02-17","current":-0.306121,"twenty":-4.487199,"median":-0.704416,"eighty":-0.217004,"marketCap":8791464},{"date":"2023-02-24","current":-0.268404,"twenty":-4.453712,"median":-0.69164,"eighty":-0.21887,"marketCap":7708271},{"date":"2023-03-03","current":-0.278653,"twenty":-4.399619,"median":-0.674554,"eighty":-0.220206,"marketCap":8002622},{"date":"2023-03-10","current":-0.295605,"twenty":-4.221882,"median":-0.670756,"eighty":-0.220476,"marketCap":8489450},{"date":"2023-03-17","current":-0.319044,"twenty":-4.206427,"median":-0.666784,"eighty":-0.220988,"marketCap":9162596},{"date":"2023-03-24","current":-0.28195,"twenty":-4.183244,"median":-0.656993,"eighty":-0.221547,"marketCap":8097283},{"date":"2023-03-31","current":-0.251749,"twenty":-4.160061,"median":-0.645586,"eighty":-0.223101,"marketCap":6085356},{"date":"2023-04-06","current":-0.180809,"twenty":-4.108543,"median":-0.632491,"eighty":-0.22144,"marketCap":4370577},{"date":"2023-04-14","current":-0.203676,"twenty":-3.992628,"median":-0.624837,"eighty":-0.218547,"marketCap":4923327},{"date":"2023-04-21","current":-0.218035,"twenty":-3.838075,"median":-0.616531,"eighty":-0.218035,"marketCap":5270402},{"date":"2023-04-28","current":-0.207399,"twenty":-3.812316,"median":-0.595341,"eighty":-0.211114,"marketCap":5013309},{"date":"2023-05-05","current":-0.186,"twenty":-3.72216,"median":-0.589774,"eighty":-0.207399,"marketCap":4496040},{"date":"2023-05-12","current":-0.170057,"twenty":-3.593365,"median":-0.578926,"eighty":-0.203676,"marketCap":4110665},{"date":"2023-05-19","current":-0.138524,"twenty":-3.078187,"median":-0.574237,"eighty":-0.198975,"marketCap":3519757},{"date":"2023-05-26","current":-0.119818,"twenty":-2.975152,"median":-0.564854,"eighty":-0.195168,"marketCap":3044461},{"date":"2023-06-02","current":-0.12184,"twenty":-2.799991,"median":-0.554475,"eighty":-0.191738,"marketCap":3095845},{"date":"2023-06-09","current":-0.11729,"twenty":-2.663469,"median":-0.544325,"eighty":-0.188162,"marketCap":2980232},{"date":"2023-06-16","current":-0.120324,"twenty":-2.403304,"median":-0.537744,"eighty":-0.185529,"marketCap":3057307},{"date":"2023-06-22","current":-0.110212,"twenty":-2.331179,"median":-0.512831,"eighty":-0.181667,"marketCap":2800390},{"date":"2023-06-30","current":-0.089484,"twenty":-2.31186,"median":-0.504284,"eighty":-0.180301,"marketCap":2273711},{"date":"2023-07-07","current":-0.108696,"twenty":-2.269358,"median":-0.500344,"eighty":-0.179074,"marketCap":2761853},{"date":"2023-07-14","current":-0.095551,"twenty":-2.235871,"median":-0.48602,"eighty":-0.176463,"marketCap":2427861},{"date":"2023-07-21","current":-0.228917,"twenty":-2.222992,"median":-0.463108,"eighty":-0.17453,"marketCap":5816563},{"date":"2023-07-28","current":-0.230007,"twenty":-2.204961,"median":-0.448416,"eighty":-0.176463,"marketCap":5844261},{"date":"2023-08-04","current":-0.212566,"twenty":-2.189506,"median":-0.439793,"eighty":-0.177048,"marketCap":5401094},{"date":"2023-08-11","current":-0.213656,"twenty":-2.17405,"median":-0.436546,"eighty":-0.178163,"marketCap":5428792},{"date":"2023-08-18","current":-0.284273,"twenty":-2.145715,"median":-0.431596,"eighty":-0.17894,"marketCap":5612832},{"date":"2023-08-25","current":-0.281373,"twenty":-2.132836,"median":-0.405938,"eighty":-0.179667,"marketCap":5555558},{"date":"2023-09-01","current":-0.268319,"twenty":-2.119956,"median":-0.373875,"eighty":-0.180213,"marketCap":5297826},{"date":"2023-09-08","current":-0.274121,"twenty":-2.107077,"median":-0.367186,"eighty":-0.180403,"marketCap":5412374},{"date":"2023-09-15","current":-0.255266,"twenty":-2.08647,"median":-0.356221,"eighty":-0.180828,"marketCap":5040094},{"date":"2023-09-22","current":-0.23061,"twenty":-2.083894,"median":-0.35054,"eighty":-0.181286,"marketCap":4553267},{"date":"2023-09-29","current":-0.197251,"twenty":-2.073591,"median":-0.336589,"eighty":-0.182977,"marketCap":3894618},{"date":"2023-10-06","current":-0.159541,"twenty":-2.068439,"median":-0.324381,"eighty":-0.181273,"marketCap":3150059},{"date":"2023-10-12","current":-0.175495,"twenty":-2.047832,"median":-0.319777,"eighty":-0.180154,"marketCap":3465064},{"date":"2023-10-20","current":-0.224808,"twenty":-2.041392,"median":-0.319097,"eighty":-0.180301,"marketCap":4438719},{"date":"2023-10-27","current":-0.15519,"twenty":-2.038816,"median":-0.31805,"eighty":-0.180213,"marketCap":3064148},{"date":"2023-11-03","current":-0.147166,"twenty":-2.034952,"median":-0.312913,"eighty":-0.177994,"marketCap":2905715},{"date":"2023-11-10","current":-0.135455,"twenty":-2.034952,"median":-0.311621,"eighty":-0.175524,"marketCap":2674479},{"date":"2023-11-17","current":-0.234708,"twenty":-2.022073,"median":-0.305807,"eighty":-0.175796,"marketCap":2957311},{"date":"2023-11-24","current":-0.219726,"twenty":-1.970555,"median":-0.300549,"eighty":-0.176418,"marketCap":2768546},{"date":"2023-12-01","current":-0.284645,"twenty":-1.951236,"median":-0.295186,"eighty":-0.17653,"marketCap":3586526},{"date":"2023-12-08","current":-0.245519,"twenty":-1.931917,"median":-0.292717,"eighty":-0.177824,"marketCap":3093536},{"date":"2023-12-15","current":-0.25718,"twenty":-1.931917,"median":-0.287495,"eighty":-0.178672,"marketCap":3240458},{"date":"2023-12-22","current":-0.26467,"twenty":-1.893278,"median":-0.287174,"eighty":-0.179342,"marketCap":3334840},{"date":"2023-12-29","current":-0.25718,"twenty":-1.839184,"median":-0.286889,"eighty":-0.179829,"marketCap":3240458},{"date":"2024-01-05","current":-0.287142,"twenty":-1.800546,"median":-0.286002,"eighty":-0.180183,"marketCap":3617987},{"date":"2024-01-12","current":-0.352061,"twenty":-1.787667,"median":-0.286889,"eighty":-0.180403,"marketCap":4435967},{"date":"2024-01-19","current":-0.29713,"twenty":-1.777363,"median":-0.287142,"eighty":-0.180809,"marketCap":3743830},{"date":"2024-01-26","current":-0.374533,"twenty":-1.738725,"median":-0.287142,"eighty":-0.180905,"marketCap":4719114},{"date":"2024-02-02","current":-0.36954,"twenty":-1.648569,"median":-0.287174,"eighty":-0.181297,"marketCap":4656192},{"date":"2024-02-09","current":-0.294633,"twenty":-1.62281,"median":-0.290994,"eighty":-0.182747,"marketCap":3712369},{"date":"2024-02-16","current":-0.476633,"twenty":-1.609931,"median":-0.289857,"eighty":-0.182811,"marketCap":6005566},{"date":"2024-02-23","current":-0.47931,"twenty":-1.589324,"median":-0.293303,"eighty":-0.183477,"marketCap":6039299},{"date":"2024-03-01","current":-0.49934,"twenty":-1.563565,"median":-0.295134,"eighty":-0.185529,"marketCap":6291674},{"date":"2024-03-08","current":-0.420937,"twenty":-1.537806,"median":-0.29713,"eighty":-0.187269,"marketCap":5303792},{"date":"2024-03-15","current":-0.401657,"twenty":-1.522351,"median":-0.301226,"eighty":-0.187592,"marketCap":5060871},{"date":"2024-03-22","current":-0.539343,"twenty":-1.509471,"median":-0.306121,"eighty":-0.187752,"marketCap":5724083},{"date":"2024-03-28","current":-0.552464,"twenty":-1.475984,"median":-0.311621,"eighty":-0.188069,"marketCap":5863337},{"date":"2024-04-05","current":-0.582158,"twenty":-1.455377,"median":-0.312913,"eighty":-0.188946,"marketCap":6178491},{"date":"2024-04-12","current":-0.520524,"twenty":-1.44765,"median":-0.317056,"eighty":-0.189992,"marketCap":5524363},{"date":"2024-04-19","current":-0.400674,"twenty":-1.43477,"median":-0.319149,"eighty":-0.190623,"marketCap":4252385},{"date":"2024-04-26","current":-0.390727,"twenty":-1.426836,"median":-0.324381,"eighty":-0.191499,"marketCap":4146813},{"date":"2024-05-03","current":-0.406665,"twenty":-1.420036,"median":-0.328965,"eighty":-0.192296,"marketCap":4315962},{"date":"2024-05-10","current":-0.38701,"twenty":-1.416739,"median":-0.333012,"eighty":-0.192744,"marketCap":4107370},{"date":"2024-05-17","current":-0.414034,"twenty":-1.409012,"median":-0.340203,"eighty":-0.194261,"marketCap":4778658},{"date":"2024-05-24","current":-0.386958,"twenty":-1.400239,"median":-0.345309,"eighty":-0.195168,"marketCap":4466149},{"date":"2024-05-31","current":-0.38446,"twenty":-1.397663,"median":-0.35054,"eighty":-0.195327,"marketCap":4437325},{"date":"2024-06-07","current":-0.35929,"twenty":-1.394844,"median":-0.352061,"eighty":-0.195908,"marketCap":4146813},{"date":"2024-06-14","current":-0.348315,"twenty":-1.39098,"median":-0.352127,"eighty":-0.196588,"marketCap":4020141},{"date":"2024-06-21","current":-0.358489,"twenty":-1.39098,"median":-0.352127,"eighty":-0.197251,"marketCap":4137567},{"date":"2024-06-28","current":-0.352192,"twenty":-1.39098,"median":-0.352192,"eighty":-0.197427,"marketCap":4064893},{"date":"2024-07-05","current":-0.295739,"twenty":-1.39098,"median":-0.352061,"eighty":-0.197948,"marketCap":3413327},{"date":"2024-07-12","current":-0.308291,"twenty":-1.39098,"median":-0.35054,"eighty":-0.199037,"marketCap":3558204},{"date":"2024-07-15","current":-0.302639,"twenty":-1.39098,"median":-0.349428,"eighty":-0.199099,"marketCap":3492971},{"date":"2024-08-02","current":-0.303954,"twenty":-1.39098,"median":-0.348315,"eighty":-0.199161,"marketCap":3508142},{"date":"2024-08-09","current":-0.241717,"twenty":-1.387116,"median":-0.345859,"eighty":-0.199565,"marketCap":2789826},{"date":"2024-08-16","current":-0.26447,"twenty":-1.380677,"median":-0.342074,"eighty":-0.199992,"marketCap":2982489},{"date":"2024-08-23","current":-0.307981,"twenty":-1.378101,"median":-0.336589,"eighty":-0.20065,"marketCap":3473180},{"date":"2024-08-30","current":-0.307305,"twenty":-1.370373,"median":-0.334845,"eighty":-0.202073,"marketCap":3465556},{"date":"2024-09-06","current":-0.364516,"twenty":-1.360069,"median":-0.341743,"eighty":-0.202979,"marketCap":4110738},{"date":"2024-09-13","current":-0.306193,"twenty":-1.352342,"median":-0.340037,"eighty":-0.203419,"marketCap":3453020},{"date":"2024-09-20","current":-0.321066,"twenty":-1.320968,"median":-0.335355,"eighty":-0.203676,"marketCap":3620738},{"date":"2024-09-27","current":-0.26527,"twenty":-1.261837,"median":-0.332941,"eighty":-0.20384,"marketCap":2991521},{"date":"2024-10-04","current":-0.225611,"twenty":-1.240811,"median":-0.332086,"eighty":-0.204208,"marketCap":2544273},{"date":"2024-10-11","current":-0.228772,"twenty":-1.222236,"median":-0.329966,"eighty":-0.204208,"marketCap":2579914},{"date":"2024-10-18","current":-0.220531,"twenty":-1.190942,"median":-0.325844,"eighty":-0.204432,"marketCap":2486982},{"date":"2024-10-25","current":-0.387436,"twenty":-1.154623,"median":-0.327156,"eighty":-0.205107,"marketCap":4369210},{"date":"2024-10-31","current":-0.78508,"twenty":-1.119973,"median":-0.329966,"eighty":-0.206243,"marketCap":8853546},{"date":"2024-11-08","current":-0.85568,"twenty":-1.097263,"median":-0.332086,"eighty":-0.207117,"marketCap":9649713},{"date":"2024-11-15","current":-1.112489,"twenty":-1.111833,"median":-0.332941,"eighty":-0.207179,"marketCap":8817483},{"date":"2024-11-22","current":-1.463005,"twenty":-1.187197,"median":-0.335355,"eighty":-0.2074,"marketCap":11595645},{"date":"2024-11-29","current":-1.219747,"twenty":-1.20095,"median":-0.339535,"eighty":-0.207404,"marketCap":9667605},{"date":"2024-12-06","current":-1.19258,"twenty":-1.236427,"median":-0.343222,"eighty":-0.208116,"marketCap":9452284},{"date":"2024-12-13","current":-1.007606,"twenty":-1.236427,"median":-0.346409,"eighty":-0.208205,"marketCap":7986196},{"date":"2024-12-20","current":-1.3089,"twenty":-1.236427,"median":-0.348396,"eighty":-0.208854,"marketCap":10374225},{"date":"2024-12-27","current":-1.541045,"twenty":-1.25409,"median":-0.351152,"eighty":-0.20886,"marketCap":12214182},{"date":"2025-01-03","current":-1.358293,"twenty":-1.336231,"median":-0.352061,"eighty":-0.209,"marketCap":10765705},{"date":"2025-01-10","current":-1.303961,"twenty":-1.349402,"median":-0.352192,"eighty":-0.209431,"marketCap":10335077},{"date":"2025-01-17","current":-1.152491,"twenty":-1.345121,"median":-0.352708,"eighty":-0.209959,"marketCap":9134538},{"date":"2025-01-24","current":-1.307254,"twenty":-1.346768,"median":-0.358489,"eighty":-0.210043,"marketCap":10361175},{"date":"2025-01-31","current":-1.104745,"twenty":-1.338865,"median":-0.359421,"eighty":-0.21027,"marketCap":8756107},{"date":"2025-02-07","current":-1.053706,"twenty":-1.330304,"median":-0.362904,"eighty":-0.210466,"marketCap":8351577},{"date":"2025-02-14","current":-0.996081,"twenty":-1.315486,"median":-0.36403,"eighty":-0.21134,"marketCap":7894850},{"date":"2025-02-21","current":-0.926932,"twenty":-1.3089,"median":-0.364942,"eighty":-0.212244,"marketCap":7346778},{"date":"2025-02-28","current":-0.864368,"twenty":-1.307254,"median":-0.367373,"eighty":-0.212536,"marketCap":6850903},{"date":"2025-03-07","current":-0.856136,"twenty":-1.303961,"median":-0.371707,"eighty":-0.212566,"marketCap":6785656},{"date":"2025-03-14","current":-0.637359,"twenty":-1.279265,"median":-0.374533,"eighty":-0.212566,"marketCap":5090547},{"date":"2025-03-21","current":-0.626307,"twenty":-1.273906,"median":-0.375127,"eighty":-0.213521,"marketCap":5002277},{"date":"2025-03-28","current":-0.548899,"twenty":-1.249136,"median":-0.377888,"eighty":-0.213656,"marketCap":4384018},{"date":"2025-04-04","current":-0.402877,"twenty":-1.247983,"median":-0.38361,"eighty":-0.213683,"marketCap":3217756},{"date":"2025-04-11","current":-0.330747,"twenty":-1.243734,"median":-0.377888,"eighty":-0.213752,"marketCap":2641651},{"date":"2025-04-17","current":-0.330747,"twenty":-1.241359,"median":-0.377888,"eighty":-0.214536,"marketCap":2641651}],"updateTime":1745068225240}}}